CBD in Postmenopausal Women With Osteopenia

Phase 1 Terminated 2 enrolled Canopy Growth Corporation NM Clinical Research & Osteoporosis Center, Inc. · collab

RandomizedParallel-groupTriple-blindSupportive care

Summary

This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.

Timeline

Start: 2022-05-01
Primary completion: 2022-09-22
Completion: 2022-09-22

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CBD	Unknown	100 mg	—
Subject	CBD	Unknown	300 mg	—

Indications

No indication recorded.